Bottom line
Semax + Selank is marketed under direct component names and labels such as "Focus & Relax." Listings span a wide total-mass range and may use acetylated names interchangeably with the parent peptide names. Those variants should not be assumed chemically equivalent. No published study of a co-formulated Semax + Selank product was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Peptide Warehouse (2026) | Semax, Selank | 5 / 5 mg | Vendor-declared; identity and contents not independently verified |
| Limitless Life Nootropics (2026) | Semax or acetylated Semax, Selank or acetylated Selank | Listing-dependent | Acetylation and parent-name usage are not consistently distinguished |
| Modern Aminos (2026) | Semax, Selank | Up to 30 / 30 mg | Vendor-declared market observation |
| American Peptides (2026) | Semax, Selank | Listing-dependent within the observed 5/5–30/30 mg range | Vendor-declared market observation |
The direct naming may look precise but does not resolve acetylation state, salt form, concentration, or whether the products are supplied together or co-formulated.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| Semax | See component monograph; parent and acetylated variants require separate identity treatment | None identified for the marketed mixture | None identified |
| Selank | See component monograph; parent and acetylated variants require separate identity treatment | None identified for the marketed mixture | None identified |
Combination-specific studies
No published peer-reviewed study of the exact marketed Semax + Selank mixture was identified. Evidence about either component separately does not establish the behavior of a co-formulation.
Safety and interaction uncertainties
Parent-versus-acetylated naming ambiguity may conceal different chemical identities.
No combination-specific human safety, interaction, pharmacokinetic, or toxicology data were identified.
Identity, purity, sterility, and compatibility cannot be inferred from a seller page.
Wide mass variation makes the marketed name a poor formulation identifier.
Regulatory and product-quality notes
"Focus & Relax" and Semax + Selank are market descriptions, not standardized formulation names.
The cited vendor pages are low-quality evidence used only to document observed names and claimed contents.
Product status must be assessed by exact substance, product, indication, and jurisdiction; a combined listing does not establish approval.
Evidence gaps
No controlled combination study
No standardized definition of acetylated versus parent variants
No independent verification across the observed mass range
No published co-formulation stability data
Sources
Peptide Warehouse. Semax + Selank market page. https://peptide-warehouse.com/ accessed 2026-08-08.
Limitless Life Nootropics. Semax/Selank market listings. https://limitlesslifenootropics.com/ accessed 2026-08-08.
Modern Aminos. Semax + Selank market page. https://modernaminos.com/ accessed 2026-08-08.
American Peptides. Semax + Selank market page. https://americanpeptides.us/ accessed 2026-08-08.